Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GlucAffect is a proprietary **powder-based dietary supplement** developed by Reliv International, designed to support blood sugar management and promote weight loss, especially in individuals with metabolic syndrome or elevated blood glucose[2][4][6][10]. Its mechanism of action is primarily mediated by a blend of ingredients with known effects on glucose metabolism and antioxidant activity. Key active ingredients include LunaRich soy powder, Pycnogenol (a natural antioxidant), omega-3 fatty acids, Madeglucyl, Glucohelp, Silbinol, salacia extract, alpha-lipoic acid, and cinnamon. Pycnogenol is clinically shown to help lower high blood glucose levels and provide additional health benefits[2][14]. Clinical studies show that, combined with diet and exercise, GlucAffect supplementation significantly reduced fasting blood glucose and promoted substantial weight loss in overweight subjects with moderately elevated blood glucose[2][4][13]. The supplement is marketed and patented by Reliv International, with proprietary formulation and manufacturing processes[2][10][14]. GlucAffect is not classified as a pharmaceutical drug, but as a nutritional supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GlucAffect.